ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance.

ABSTRACT:

Background

Triple-negative breast cancer (TNBC) is a subtype of breast cancer with limited treatment options and poor prognosis. This study aimed to identify potential therapeutic targets based on the expression profiles of differentially expressed genes (DEGs) in TNBC.

Methods

The Limma package was used to identify DEGs in TCGA and GEO datasets. Immunohistochemical (IHC) analysis and western blotting were used to determine the expression of ZDHHC9 in TNBC tissues. Flow cytometry assay and tissue immunofluorescence analysis were used to detect infiltration of multiple immune cells in tumor tissue at different levels of ZDHHC9 expression.

Results

ZDHHC9 was identified as a key factor associated with resistance to ICB therapy through weighted gene co-expression network

SUBMITTER: Xu C 

PROVIDER: S-EPMC10597932 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature